{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T08:05:13Z","timestamp":1776413113430,"version":"3.51.2"},"reference-count":38,"publisher":"Academy of Managed Care Pharmacy","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMCP"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.18553\/jmcp.2026.32.2.166","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T15:32:00Z","timestamp":1770219120000},"page":"166-175","source":"Crossref","is-referenced-by-count":1,"title":["Beyond glycemic control: Sex differences shaping glucagon-like peptide-1 receptor agonist utilization in the United States"],"prefix":"10.18553","volume":"32","author":[{"given":"Samuel C.","family":"Ofili","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7818","reference":[{"key":"r1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-55524-w"},{"key":"r2","doi-asserted-by":"publisher","DOI":"10.1126\/science.adn4128"},{"key":"r3","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01710-0"},{"key":"r4","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2015.1090295"},{"key":"r5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1085799"},{"key":"r6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00536-5"},{"key":"r7","unstructured":"Major Increase in Prescribed Drugs Ozempic\n                      \u00ae\n                      & Mounjaro\n                      \u00ae\n                      . Accessed May 21, 2025. https:\/\/www.trillianthealth.com\/market-research\/studies\/patients-prescribed-drugs-like-ozempic-and-mounjaro-have-increased-over-300-percent"},{"key":"r8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"r9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"r10","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-021-00453-x"},{"key":"r11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.7112"},{"key":"r12","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16318"},{"key":"r13","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-1082"},{"key":"r14","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-020-04987-2"},{"key":"r15","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15473"},{"key":"r16","doi-asserted-by":"publisher","DOI":"10.1177\/08901171251335507b"},{"key":"r17","unstructured":"AHRQ. Medical Expenditure Panel Survey Home. Accessed May 30, 2025. https:\/\/meps.ahrq.gov\/mepsweb\/"},{"key":"r18","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-24-02878"},{"key":"r19","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-024-08961-x"},{"key":"r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2024.07.003"},{"key":"r21","unstructured":"AHRQ. Medical Expenditure Panel Survey Download Data Files. Accessed December 10, 2025. https:\/\/meps.ahrq.gov\/data_stats\/download_data_files.jsp"},{"key":"r22","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199801000-00004"},{"key":"r23","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4617"},{"key":"r24","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S214909"},{"key":"r25","doi-asserted-by":"publisher","DOI":"10.1177\/1557988316681221"},{"key":"r26","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.70063"},{"key":"r27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2016.01.013"},{"key":"r28","first-page":"123","volume":"6","author":"Anichini R","year":"2013","journal-title":"Diabetes Metab Syndr Obes"},{"key":"r29","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2010.03.009"},{"key":"r30","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ16-0552"},{"key":"r31","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13086"},{"key":"r32","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.765446"},{"key":"r33","doi-asserted-by":"publisher","DOI":"10.1007\/s40501-024-00331-y"},{"key":"r34","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103385"},{"key":"r35","doi-asserted-by":"crossref","unstructured":"Yao Y, Chen L, Chen X, Tian X, Zhou W. Real-world data in pharmacovigilance database provides a new perspective for understanding the psychiatric adverse events associated with glucagon-like peptide-1 receptor agonists (Glp-1 RAs) exposure.\n                      Heliyon.\n                      Published online July 28, 2024. doi:10.2139\/ssrn.4901779","DOI":"10.2139\/ssrn.4901779"},{"key":"r36","doi-asserted-by":"publisher","DOI":"10.2217\/dmt.13.41"},{"issue":"1","key":"r37","first-page":"S207","volume":"48","author":"ElSayed NA","year":"2025","journal-title":"Diabetes Care"},{"key":"r38","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-0472"}],"container-title":["Journal of Managed Care & Specialty Pharmacy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T15:32:02Z","timestamp":1770219122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jmcp.org\/doi\/10.18553\/jmcp.2026.32.2.166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.18553\/jmcp.2026.32.2.166"],"URL":"https:\/\/doi.org\/10.18553\/jmcp.2026.32.2.166","relation":{},"ISSN":["2376-0540","2376-1032"],"issn-type":[{"value":"2376-0540","type":"print"},{"value":"2376-1032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}